Waltenburg M, Kainulainen M, Whitesell A, Nyakarahuka L, Baluku J, Kyondo J
Vaccine. 2024; 42(22):126031.
PMID: 38880693
PMC: 11841019.
DOI: 10.1016/j.vaccine.2024.05.079.
Zarate-Sanchez E, George S, L Moya M, Robertson C
Biofabrication. 2024; 16(3).
PMID: 38749416
PMC: 11151171.
DOI: 10.1088/1758-5090/ad4c0b.
Santos R, Ilinykh P, Pietzsch C, Ronk A, Huang K, Kuzmina N
Cell Rep. 2023; 42(10):113254.
PMID: 37858466
PMC: 10664807.
DOI: 10.1016/j.celrep.2023.113254.
Kainulainen M, Harmon J, Whitesell A, Bergeron E, Karaaslan E, Cossaboom C
Emerg Microbes Infect. 2023; 12(2):2265660.
PMID: 37787119
PMC: 10623891.
DOI: 10.1080/22221751.2023.2265660.
Olejnik J, Hume A, Ross S, Scoon W, Seitz S, White M
Pathogens. 2023; 12(7).
PMID: 37513799
PMC: 10386221.
DOI: 10.3390/pathogens12070952.
A Single-Dose Intranasal Combination Panebolavirus Vaccine.
Malherbe D, Kimble J, Atyeo C, Fischinger S, Meyer M, Cody S
J Infect Dis. 2023; 228(Suppl 7):S648-S659.
PMID: 37469133
PMC: 10651208.
DOI: 10.1093/infdis/jiad266.
Ebolavirus Species-Specific Interferon Antagonism Mediated by VP24.
Ramanathan P, Tigabu B, Santos R, Ilinykh P, Kuzmina N, Vogel O
Viruses. 2023; 15(5).
PMID: 37243162
PMC: 10222226.
DOI: 10.3390/v15051075.
Fluorescent and Bioluminescent Reporter Mouse-Adapted Ebola Viruses Maintain Pathogenicity and Can Be Visualized in Vivo.
Davies K, Welch S, Jain S, Sorvillo T, Coleman-McCray J, Montgomery J
J Infect Dis. 2023; 228(Suppl 7):S536-S547.
PMID: 37145895
PMC: 11014640.
DOI: 10.1093/infdis/jiad136.
Systematic analysis of human antibody response to ebolavirus glycoprotein shows high prevalence of neutralizing public clonotypes.
Chen E, Gilchuk P, Zost S, Ilinykh P, Binshtein E, Huang K
Cell Rep. 2023; 42(4):112370.
PMID: 37029928
PMC: 10556194.
DOI: 10.1016/j.celrep.2023.112370.
Labeling Ebola Virus with a Self-Splicing Fluorescent Reporter.
Heiden B, Muhlberger E, Lennon C, Hume A
Microorganisms. 2022; 10(11).
PMID: 36363701
PMC: 9696229.
DOI: 10.3390/microorganisms10112110.
Effects of Overexpression of the Egyptian Fruit Bat Innate Immune Genes on Filovirus Infections in the Host Cells.
Kuzmin I, Ramanathan P, Basler C, Bukreyev A
Front Virol. 2022; 1.
PMID: 36237518
PMC: 9555311.
DOI: 10.3389/fviro.2021.759655.
Ebola virus infection induces a delayed type I IFN response in bystander cells and the shutdown of key liver genes in human iPSC-derived hepatocytes.
Scoon W, Mancio-Silva L, Suder E, Villacorta-Martin C, Lindstrom-Vautrin J, Bernbaum J
Stem Cell Reports. 2022; 17(10):2286-2302.
PMID: 36084636
PMC: 9561183.
DOI: 10.1016/j.stemcr.2022.08.003.
Assessment of Life Cycle Modeling Systems as Prediction Tools for a Possible Attenuation of Recombinant Ebola Viruses.
Bodmer B, Hoenen T
Viruses. 2022; 14(5).
PMID: 35632785
PMC: 9147524.
DOI: 10.3390/v14051044.
Ubiquitination of Ebola virus VP35 at lysine 309 regulates viral transcription and assembly.
van Tol S, Kalveram B, Ilinykh P, Ronk A, Huang K, Aguilera-Aguirre L
PLoS Pathog. 2022; 18(5):e1010532.
PMID: 35533195
PMC: 9119628.
DOI: 10.1371/journal.ppat.1010532.
Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication.
Tripp R, Martin D
Viruses. 2022; 14(3).
PMID: 35337018
PMC: 8955960.
DOI: 10.3390/v14030612.
Functional interactomes of the Ebola virus polymerase identified by proximity proteomics in the context of viral replication.
Fang J, Pietzsch C, Tsaprailis G, Crynen G, Cho K, Ting A
Cell Rep. 2022; 38(12):110544.
PMID: 35320713
PMC: 10496643.
DOI: 10.1016/j.celrep.2022.110544.
Pan-ebolavirus protective therapy by two multifunctional human antibodies.
Gilchuk P, Murin C, Cross R, Ilinykh P, Huang K, Kuzmina N
Cell. 2021; 184(22):5593-5607.e18.
PMID: 34715022
PMC: 8716180.
DOI: 10.1016/j.cell.2021.09.035.
Interferon-alpha or -beta facilitates SARS-CoV-2 pulmonary vascular infection by inducing ACE2.
Klouda T, Hao Y, Kim H, Kim J, Olejnik J, Hume A
Angiogenesis. 2021; 25(2):225-240.
PMID: 34714440
PMC: 8554520.
DOI: 10.1007/s10456-021-09823-4.
Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma.
Gilchuk P, Guthals A, Bonissone S, Shaw J, Ilinykh P, Huang K
Front Immunol. 2021; 12:706757.
PMID: 34335620
PMC: 8322977.
DOI: 10.3389/fimmu.2021.706757.
Development of a New Reverse Genetics System for Ebola Virus.
Gan T, Zhou D, Huang Y, Xiao S, Ma Z, Hu X
mSphere. 2021; 6(3).
PMID: 33952663
PMC: 8103987.
DOI: 10.1128/mSphere.00235-21.